ES2062221T3 - Un procedimiento para la micronizacion de un farmaco ligeramente soluble. - Google Patents

Un procedimiento para la micronizacion de un farmaco ligeramente soluble.

Info

Publication number
ES2062221T3
ES2062221T3 ES90114858T ES90114858T ES2062221T3 ES 2062221 T3 ES2062221 T3 ES 2062221T3 ES 90114858 T ES90114858 T ES 90114858T ES 90114858 T ES90114858 T ES 90114858T ES 2062221 T3 ES2062221 T3 ES 2062221T3
Authority
ES
Spain
Prior art keywords
micronization
procedure
slightly soluble
pharmacy
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90114858T
Other languages
English (en)
Inventor
Masayoshi Samejima
Kazuo Noda
Masao Kobayashi
Takashi Osawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Application granted granted Critical
Publication of ES2062221T3 publication Critical patent/ES2062221T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

UN PROCESO PARA MICRONIZAR DROGAS SOLUBLES LIGERAMENTE, CARACTERIZADO POR SOMETER UNA MEZCLA DE DICHA DROGA Y UN AZUCAR O ALCOHOL DE AZUCAR A COMMINUCION DE IMPACTO O DE AGITADO DE ALTA VELOCIDAD. TAMBIEN ES PROVISTO UNA FORMULA FARMACEUTICA QUE COMPRENDE LA DROGA MICRONIZADA.
ES90114858T 1989-08-04 1990-08-02 Un procedimiento para la micronizacion de un farmaco ligeramente soluble. Expired - Lifetime ES2062221T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1204132A JP2642486B2 (ja) 1989-08-04 1989-08-04 難溶性薬物の超微粒子化法

Publications (1)

Publication Number Publication Date
ES2062221T3 true ES2062221T3 (es) 1994-12-16

Family

ID=16485367

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90114858T Expired - Lifetime ES2062221T3 (es) 1989-08-04 1990-08-02 Un procedimiento para la micronizacion de un farmaco ligeramente soluble.

Country Status (9)

Country Link
US (1) US5202129A (es)
EP (1) EP0411629B1 (es)
JP (1) JP2642486B2 (es)
KR (1) KR0126465B1 (es)
AT (1) ATE96658T1 (es)
CA (1) CA2022465C (es)
DE (1) DE69004372T2 (es)
DK (1) DK0411629T3 (es)
ES (1) ES2062221T3 (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
FR2684298B1 (fr) * 1991-12-03 1994-03-11 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques solides a base de derives de lapiperidine substitues en 1,4.
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US7336788B1 (en) * 1992-12-09 2008-02-26 Discovery Communicatoins Inc. Electronic book secure communication with home subsystem
CA2150372C (en) * 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US20070116761A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US7865567B1 (en) 1993-12-02 2011-01-04 Discovery Patent Holdings, Llc Virtual on-demand electronic book
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
AU3154895A (en) * 1994-08-01 1996-03-04 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
KR100389080B1 (ko) 1994-12-22 2003-10-17 아스트라제네카 악티에볼라그 부갑상선호르몬(pth)을포함하는흡입용치료제제
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CZ288146B6 (en) 1994-12-22 2001-05-16 Astra Ab Pharmaceutical aerosol preparation, process of its preparation and use
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
BRPI9810945B8 (pt) * 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
ZA991922B (en) 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
US6197347B1 (en) 1998-06-29 2001-03-06 Andrx Pharmaceuticals, Inc. Oral dosage for the controlled release of analgesic
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US6500462B1 (en) * 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
ES2240222T3 (es) 1999-12-20 2005-10-16 Nicholas J. Kerkhof Procedimiento para producir particulas nanometricas mediante secado por pulverizacion en lecho fluidizado.
CA2419081A1 (en) * 2000-08-14 2002-02-21 Teva Pharmaceuticals Industries Ltd. Micronized torsemide
US6932861B2 (en) * 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
AU2002225763A1 (en) 2000-11-28 2002-06-11 Fmc Corporation Edible pga(propylene glycol alginate) coating composition
US6544552B2 (en) 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
EP2135611A1 (en) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
ES2247336T3 (es) * 2001-06-29 2006-03-01 Eurand Pharmaceuticals Ltd Procedimiento de activacion de farmacos mediante una trituradora vibracional.
WO2007064311A1 (en) * 2001-07-10 2007-06-07 Teva Pharmaceutical Industries Ltd. Micronized mirtazapine
CA2456806C (en) * 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7033602B1 (en) * 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7794743B2 (en) * 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040146537A1 (en) * 2003-01-28 2004-07-29 Ramachandran Radhakrishnan Oily wax matrix suspension formulation comprising pharmacologically active agents
CA2511992A1 (en) * 2003-02-24 2004-09-10 Mallinckrodt Inc. Process for preparing benzhydrylthioacetamide
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
KR100767271B1 (ko) * 2003-07-11 2007-10-17 에프. 호프만-라 로슈 아게 사퀴나비르 메실레이트 경구 투여 형태
TWI337877B (en) * 2003-07-18 2011-03-01 Santarus Inc Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
WO2005051511A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Chemical Corporation 有機化合物微粒子の製造方法
WO2005070393A2 (en) * 2004-01-08 2005-08-04 Wyeth Directly compressible pharmaceutical composition of the rapamycin ester cci-779
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
ES2231043B2 (es) * 2004-10-29 2005-10-01 Laboratorios Cinfa, S.A. Composicion farmaceutica de ebastina de liberacion inmediata y su proceso de fabricacion.
JP4754211B2 (ja) * 2004-12-28 2011-08-24 ライオン株式会社 粒状医薬組成物及びその製造方法
CN104083342A (zh) * 2004-12-31 2014-10-08 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
PT1920786E (pt) 2005-07-25 2011-12-28 Otsuka Pharma Co Ltd Preparação oral para avaliar a capacidade metabólica da pirimidina
KR101409302B1 (ko) * 2005-08-02 2014-06-20 드로싸팜 아게 인도메타신 및/또는 아세메타신을 포함하는 약학적 조성물
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
EP1973523A2 (en) * 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
EP1849459A1 (en) * 2006-03-06 2007-10-31 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
JP2007314529A (ja) * 2006-04-28 2007-12-06 Lion Corp 造粒粒子、錠剤、及び造粒粒子の製造方法
AU2012203877B2 (en) * 2006-06-30 2013-10-10 Iceutica Pty Ltd Methods For The Preparation Of Biologically Active Compounds In Nanoparticulate Form
NZ599069A (en) * 2006-06-30 2013-10-25 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form
AU2013273795C1 (en) * 2006-06-30 2016-08-18 Iceutica Pty Ltd Method for the Preparation of Biologically Active Compounds in Nanoparticle Form
IN2014MN00380A (es) 2006-06-30 2015-06-19 Iceutica Pty Ltd
AU2016203251B2 (en) * 2006-06-30 2017-11-16 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
ES2644803T5 (es) * 2007-03-29 2024-02-26 Daiichi Sankyo Co Ltd Composición farmacéutica
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
CN102014918A (zh) * 2007-04-20 2011-04-13 太阳医药工业有限公司 由微量沉淀产生的药学组合物
JP2009091298A (ja) * 2007-10-10 2009-04-30 Asuka Corporation:Kk 皮膚改善化粧料
EP2252284B1 (en) * 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
NZ587169A (en) * 2008-02-06 2011-03-31 Wockhardt Research Center Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
US20170105966A1 (en) * 2008-02-28 2017-04-20 Roger Imboden Pharmaceutical composition containing indometacin and/or acemetacin
US8252947B2 (en) 2008-04-03 2012-08-28 Harbor Therapeutics, Inc. Solid state forms of a pharmaceutical
JP5149673B2 (ja) * 2008-04-03 2013-02-20 有限会社不動権現 こんにゃく粉製造方法
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
WO2010032434A1 (ja) * 2008-09-19 2010-03-25 株式会社アクティバスファーマ 医療用複合有機化合物粉体、その製造方法ならびに懸濁液
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
BRPI1014278B8 (pt) * 2009-04-24 2021-05-25 Iceutica Pty Ltd método para produzir uma forma de dosagem compreendendo metaxolona, forma de dosagem, composição farmacêutica compreendendo a referida forma de dosagem e uso da mesma
EA201171282A1 (ru) * 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Способ производства коммерческих порошков, содержащих нано- и микрочастицы
MY177537A (en) * 2009-04-24 2020-09-17 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
BRPI1014272A2 (pt) 2009-04-24 2016-10-18 Iceutica Pty Ltd nova formulação de diclofenac
MX344222B (es) * 2009-04-24 2016-12-07 Iceutica Pty Ltd Una formulacion novedosa de naproxeno.
CA2759125C (en) 2009-04-24 2017-08-15 Iceutica Pty Ltd A novel formulation of indomethacin
KR101873500B1 (ko) * 2009-04-24 2018-08-02 아이슈티카 피티와이 리미티드 생물학적 활성 물질의 용해 프로파일 개선방법
EP2484383B1 (en) 2009-09-30 2021-04-28 Kabushiki Kaisha Sangi Method for improving the aqueous solubility of poorly-soluble substances
ES2601884T3 (es) 2010-03-19 2017-02-16 Daiichi Sankyo Company, Limited Procedimiento para mejorar la capacidad de disolución de un anticoagulante
CN102858682B (zh) 2010-03-22 2014-07-16 株式会社Bio-Synectics 纳米颗粒制备方法
CN102408756B (zh) * 2011-08-05 2013-06-19 中国人民解放军第四军医大学 DiI 显微颗粒简易制作及其标记神经元的方法
ES2673182T3 (es) 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
KR101794032B1 (ko) 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
CA2882528A1 (en) 2012-08-20 2014-02-27 Otsuka Pharmaceutical Co., Ltd. Method for measuring carbohydrate metabolism ability, and composition for use in said method
KR20210014204A (ko) 2013-03-15 2021-02-08 오츠카 세이야쿠 가부시키가이샤 지방산 연소에 의한 인슐린 저항성의 측정 방법, 및 그에 사용하는 조성물
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2017209216A1 (ja) * 2016-05-31 2017-12-07 協和発酵キリン株式会社 難溶性薬物の微粒子を含有する医薬組成物の製造方法
ES2813561T3 (es) 2017-09-07 2021-03-24 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica en comprimido que comprende bilastina
ES2835287T3 (es) 2017-12-18 2021-06-22 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio
WO2020179025A1 (ja) * 2019-03-06 2020-09-10 株式会社伊藤園 植物含有組成物の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA952431A (en) * 1970-09-28 1974-08-06 Frank M. Bardani Controlled release medicament
FR2162245A1 (en) * 1971-12-06 1973-07-20 Sobio Lab Micronized l-dopa - with increased bioavailability
FR2257266B1 (es) * 1974-01-10 1977-07-01 Pasteur Institut
DE2401037C2 (de) * 1974-01-10 1978-03-30 Eric G. 7000 Stuttgart Doubleday Rohrstück für Reinigungsmaschinen, insbesondere für Staub- oder Flüssigkeitssauggeräte
JPS5132718A (en) * 1974-09-13 1976-03-19 Yoshinobu Nakai Nanyoseiyakuhin no yoshutsusokudochosetsuho
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
JPH0215026A (ja) * 1988-07-01 1990-01-18 Takada Seiyaku Kk 新規なプロブコール固形製剤
HU200926B (en) * 1988-10-28 1990-09-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules

Also Published As

Publication number Publication date
JPH0366613A (ja) 1991-03-22
EP0411629A3 (en) 1991-05-08
KR910004183A (ko) 1991-03-28
DK0411629T3 (da) 1993-12-13
CA2022465C (en) 1998-04-21
ATE96658T1 (de) 1993-11-15
CA2022465A1 (en) 1991-02-05
JP2642486B2 (ja) 1997-08-20
EP0411629A2 (en) 1991-02-06
DE69004372D1 (de) 1993-12-09
US5202129A (en) 1993-04-13
EP0411629B1 (en) 1993-11-03
KR0126465B1 (ko) 1997-12-24
DE69004372T2 (de) 1994-04-21

Similar Documents

Publication Publication Date Title
ES2062221T3 (es) Un procedimiento para la micronizacion de un farmaco ligeramente soluble.
AU4161589A (en) 7-substituted derivatives of 3,5-dihydroxyhept-6-ynoic acid, a process for the preparation thereof, the use thereof as pharmaceuticals, and intermediates
HUT46657A (en) Process for producing antitumour pharmaceutical compositions comprising sulfonyl-urea derivatives as active ingredient
HU905827D0 (en) Process for producing 4-hydroxi-tetrahydro-pyrane-2-one derivatives as well as corresponding dihydroxi-carboxylic acid derivatives and pharmaceutical preparatives containing these compounds
EP0404283A3 (de) 11-Beta-aryl-4-estrene, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
HUT51620A (en) Process for producing multicyclic pyrimidine derivatives and pharmaceutical preparations containing these compounds as active substance
BR9304431A (pt) Medicamento processo para sua preparaçao e aplicaçao de uma mistura
HUT53897A (en) Process for producing benzopyran derivatives and pharmaceutical compositions comprising such compounds as active ingredient
AU1950388A (en) Pharmaceutical formulation ensuring the transdermal absorption of the active ingredient and process for preparing same
FR2422640A1 (fr) Nouvelles morphinane-6-ones a substituant 8b-alkyle, leur procede de production et medicament les contenant
PT89214A (pt) Processo para a preparacao de novos derivados de aminoacidos ciclicos e de composicoes farmaceuticas que os contem
HUT59116A (en) Process for producing oxazole derivatives and pharmaceutical compositions comprising oxazole derivatives as active ingredient
HUT47233A (en) Process for producing pharmaceutical comprising phenol derivatives as active ingredient and for producing the active ingredients
RU94016184A (ru) Противоаллергическая композиция для местного глазного применения, способ ее получения
HUT55379A (en) Process for producing new pyridone derivatives and pharmaceutical compositions containing them
HUT48232A (en) Process for producing new biphenyl derivatives and pharmaceutical compositions comprising such compounds as active ingredient
WO1993017691A3 (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
AU3668584A (en) Pharmaceutical preparations containing a phospholipidan an oxicam derivative
PT87301A (pt) Process for the preparation of 1,3-dioxanes by products and of pharmaceutical compounds containing them
IL91212A0 (en) 6-fluoro-3,5-dihydroxy carboxylic acids and derivatives thereof,a process for the preparation thereof and pharmaceutical compositions containing them
HUT47077A (en) Process for producing hydrocinnamomic acid derivatives and pharmaceutical compositions containing them as active components
IL88222A0 (en) Medicaments comprising 2-pyrimidinyl-1-piperazine derivatives
ZA882854B (en) Substituted quinoxalyl-imidazolidine-2,4-diones,processes for their preparation,their use as medicaments and pharmaceutical preparations
PT84405B (pt) Processo para a preparacao de composicoes farmaceuticas contendo 2-alcoxi-n-(1-azabiciclo {2.2.2} octil-3-benzamida-n-oxidos apropriadas para controlar a emese provocada por drogas anti-cancro
PT87304A (pt) Processo para a preparacao de derivados de benzenosulfonamida e de composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 411629

Country of ref document: ES